AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes
Minke A.E. Rab(Utrecht University), Richard van Wijk(Utrecht University), Kendall Johnson(Arup Group (United States)), Gerard Pasterkamp(University Medical Center Utrecht), Victor Chubukov(Agios Pharmaceuticals (United States)), Penelope A. Kosinski(Agios Pharmaceuticals (United States)), Jeffrey Hixon(Q Therapeutics (United States)), Wouter W. van Solinge(Utrecht University), Stephanie van Straaten(Utrecht University), Brigitte A. van Oirschot(Utrecht University), Lenny Dang(Millennium Engineering and Integration (United States)), Charles Kung(Agios Pharmaceuticals (United States)), Eduard J. van Beers(Utrecht University)
Cited by 81
Related Papers
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2020|1.5k
Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
|Cancer Cell|2007|949
Microanatomy of the Human Atherosclerotic Plaque by Single-Cell Transcriptomics
|Circulation Research|2020|577